The primary objective of this trial was to demonstrate , based on the estimated glomerular filtration rate ( eGFR ) , superior renal function at month 12 after conversion of maintenance kidney transplant patients from calcineurin inhibitor ( CNI ) therapy to everolimus , compared to continuing a standard CNI regimen .